OSI Systems, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2013; filed August 16, 2013. The request references “2012 Q4,” but the supplied filing is the fiscal 2013 annual report and includes unaudited quarterly data for the quarter ended June 30, 2013.
Business Context
OSI Systems designs and manufactures specialized electronic systems and components for homeland security, healthcare, defense, aerospace and industrial applications. Its three divisions are Security, Healthcare, and Optoelectronics and Manufacturing. Fiscal 2013 revenue was generated approximately 46% by Security, 29% by Healthcare and 25% by Optoelectronics and Manufacturing.
Key Financial Metrics
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Revenue | $802.0 million | $793.0 million | Up 1% |
| Gross profit | $290.4 million | $268.6 million | Up 8% |
| Gross margin | 36.2% | 33.9% | Up 230 basis points |
| Operating income | $74.4 million | $65.9 million | Up 13% |
| Net income | $44.1 million | $45.5 million | Down 3% |
| Diluted EPS | $2.15 | $2.24 | Down 4% |
| Cash flow from operations | $58.7 million | $120.6 million | Down 51% |
| Capital expenditures | $157.4 million | $68.5 million | Up 130% |
| Cash and equivalents | $34.7 million | $91.5 million | Down 62% |
| Total debt | $71.5 million | $2.7 million | Up $68.8 million |
FY2013 products generated $600.3 million of revenue, while services generated $201.8 million. Service revenue increased substantially, primarily due to the expansion of turnkey security screening services.
At June 30, 2013, working capital was $245.3 million, total assets were $919.8 million and stockholders’ equity was $478.5 million. The company had no declared cash dividend and stated that it did not expect to pay dividends in the foreseeable future.
Material Changes Versus the Prior Comparable Period
- Security revenue declined 5% to $372.2 million because fiscal 2012 included $94.7 million from a large hardware integration contract. Excluding that contract, Security revenue increased approximately 23%, driven mainly by turnkey screening services.
- Healthcare revenue declined 2% to $231.3 million, reflecting lower anesthesia and cardiology revenue, partly offset by growth in patient monitoring.
- Optoelectronics and Manufacturing revenue increased 20% to $198.5 million, primarily from a 50% increase in contract manufacturing revenue.
- Gross margin improved because turnkey screening services generally produce higher margins and the prior-year hardware integration contract had comparatively low margins.
- Operating expenses increased 7% to $216.0 million. Impairment, restructuring and other charges rose to $8.0 million from $1.4 million, including $3.2 million related to a TSA contract settlement and $1.1 million of software impairment.
- Net income declined despite higher operating income, primarily because income tax expense increased to $25.3 million from $16.4 million. A $6.8 million non-cash tax charge resulted from accelerating tax depreciation of assets related to the Mexico program; excluding this charge, the effective tax rate would have been approximately 26.6%.
- Cash flow and liquidity weakened as the company invested heavily in the Mexico turnkey program and acquired a new Healthcare headquarters and manufacturing facility.
Fourth-Quarter Information
| Quarter ended June 30, 2013 | Amount |
|---|---|
| Revenue | $227.9 million |
| Gross profit | $87.1 million |
| Income from operations | $26.2 million |
| Net income | $11.8 million |
| Diluted EPS | $0.58 |
Debt, Liquidity and Commitments
- The company had a $425 million revolving credit facility maturing in November 2016, with $59.0 million drawn at June 30, 2013. The facility also supported approximately $119.5 million of outstanding letters of credit.
- Total debt included $59.0 million under the revolving facility and approximately $12.5 million of term loans, including a $10.0 million balance on a seven-year loan used to acquire the Washington facility.
- Contractual obligations totaled approximately $146.1 million, including $71.5 million of debt, $24.1 million of operating leases, $42.5 million of purchase obligations and $8.0 million of defined-benefit obligations. Additional letters of credit totaled approximately $124.7 million.
- Management stated that operating cash flow, existing borrowing arrangements and future capital-market access were expected to satisfy foreseeable cash requirements, subject to operating performance, covenant compliance and capital-market conditions.
Guidance, Outlook, Risks and Unusual Items
- The filing does not provide a specific numerical revenue, earnings or margin forecast for fiscal 2014.
- Management intended to continue investing in research and development, pursue selective acquisitions and expand turnkey security screening, healthcare technologies and contract manufacturing.
- The Mexico turnkey security program is a major growth initiative but requires substantial upfront capital, personnel and infrastructure. The company received a $100 million customer advance and must provide a guarantee until the advance is earned.
- Backlog was approximately $1.0 billion at June 30, 2013, down from approximately $1.1 billion in 2012. Management cautioned that backlog is not necessarily indicative of future revenue because of project timing, cancellations, customer requirements and acceptance testing.
- Rapiscan subsidiaries entered into a 30-month Administrative Agreement with the U.S. Department of Homeland Security in June 2013, resolving a proposed debarment related to the Secure 1000SP system and associated software. Noncompliance could lead to renewed debarment proceedings.
- The company expects additional fiscal 2014 costs related to relocating Healthcare operations from Issaquah, Washington, to Snoqualmie, Washington.
- Risks include government budget reductions and contract termination rights, Mexico execution and payment risks, foreign exchange exposure, intense competition, medical-device regulation, product liability and recalls, supply-chain concentration, cybersecurity, environmental contamination at the Hawthorne facility, and compliance with debt covenants.
- A 10% appreciation of the U.S. dollar against relevant local currencies would have increased estimated fiscal 2013 operating income by approximately $8.0 million; a 10% depreciation would have reduced it by a similar amount.
Investor Verification Checklist
- Verify the current status, economics, remaining capital requirements and guarantee obligations of the Mexico turnkey screening contract.
- Review the credit facility’s borrowing capacity, letters of credit, covenant headroom and November 2016 maturity.
- Assess whether the improvement in gross margin is sustainable after normalization for the prior-year large hardware contract and changes in segment mix.
- Monitor Healthcare revenue recovery, particularly anesthesia and cardiology, and the financial impact of the facility relocation.
- Evaluate the TSA/DHS Administrative Agreement and any continuing product, legal or government-contract exposure.
- Review cash conversion, accounts receivable growth, inventory levels and the significant increase in capital expenditures.
- Assess potential environmental remediation costs at the Hawthorne facility; the filing states that no liability was accrued because the amount was not considered probable or reasonably estimable.
- Consider the effect of the $16.4 million of fiscal 2013 stock-based compensation expense, contingent acquisition obligations of up to $45 million, and other unrecognized tax benefits of $6.9 million.